Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

The collaboration will leverage Orbit’s expertise and bead-based peptide display engine for the identification, screening, and selection of cyclic peptides specific to a wide range of disease targets, to be paired with Secarna’s ASO molecules. The addition of cyclic peptides to Secarna’s proprietary ASO discovery and development platform will expand its therapeutic spectrum, positioning it to develop targeted antisense assets beyond modalities such as antibodies and sugar molecules, like GalNAc.

We are very pleased to embark on this collaboration with Orbit Discovery, as the team’s expertise in peptide discovery and development will further enhance our capabilities for the development of targeted antisense therapeutics

Konstantin Petropoulos, CBO, Secarna Pharmaceuticals. 

“We look forward to working with Orbit to expand both the therapeutic potential and universe of targeted ASO therapeutics with highly specific, potent, safe and convenient therapeutic options available for patients who urgently need them.”

Orbit’s peptide discovery services enable the screening of large libraries of peptides through the combination of DNA-encoded libraries and bead-based presentation. The proprietary technology is uniquely equipped to address soluble targets and targets in situ, both on and in cells, allowing for faster discovery times of relevant peptide leads based on affinity screens and/or functional screens.

The collaboration not only strengthens Secarna's ability to create targeted antisense therapeutics, paired to cyclic peptides, but will also extend the reach of antisense approaches, potentially offering new treatment options for a wider range of diseases.

“Together with Secarna, we are excited to address the growing need for effective and highly specific targeted therapeutics, focused on enabling new options for the way innovative ASO therapies are delivered”, said Dr. Neil Butt, Chief Executive Officer, Orbit Discovery. “This collaboration is further validation of our expertise in the discovery of targeting peptide conjugates, and adds to our growing portfolio of partners that share our goal of delivering a generation of therapeutics with lower toxicity and better tissue specificity that will ultimately be safer and more effective for patients globally.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Secarna Pharmaceuticals. (2024, May 29). Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics. News-Medical. Retrieved on June 12, 2024 from https://www.news-medical.net/news/20240529/Secarna-Pharmaceuticals-and-Orbit-Discovery-enter-collaboration-to-discover-and-develop-peptide-conjugated-targeted-antisense-oligonucleotide-therapeutics.aspx.

  • MLA

    Secarna Pharmaceuticals. "Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics". News-Medical. 12 June 2024. <https://www.news-medical.net/news/20240529/Secarna-Pharmaceuticals-and-Orbit-Discovery-enter-collaboration-to-discover-and-develop-peptide-conjugated-targeted-antisense-oligonucleotide-therapeutics.aspx>.

  • Chicago

    Secarna Pharmaceuticals. "Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics". News-Medical. https://www.news-medical.net/news/20240529/Secarna-Pharmaceuticals-and-Orbit-Discovery-enter-collaboration-to-discover-and-develop-peptide-conjugated-targeted-antisense-oligonucleotide-therapeutics.aspx. (accessed June 12, 2024).

  • Harvard

    Secarna Pharmaceuticals. 2024. Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics. News-Medical, viewed 12 June 2024, https://www.news-medical.net/news/20240529/Secarna-Pharmaceuticals-and-Orbit-Discovery-enter-collaboration-to-discover-and-develop-peptide-conjugated-targeted-antisense-oligonucleotide-therapeutics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.